Immutep Ltd Issues 4.8 Million New Securities on ASX

Story Highlights
Immutep Ltd Issues 4.8 Million New Securities on ASX

Immutep Ltd ( (AU:IMM) ) has issued an announcement.

Immutep Ltd has announced the issuance of 4,800,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and support its ongoing development projects. The issuance of these securities is expected to strengthen Immutep’s financial position, potentially impacting its market presence and providing additional resources for its research and development initiatives.

More about Immutep Ltd

Immutep Ltd is a biotechnology company that focuses on developing immunotherapy treatments for cancer and autoimmune diseases. The company is involved in the research and development of innovative therapies that aim to harness the body’s immune system to fight diseases, positioning itself as a key player in the biotech industry.

YTD Price Performance: -9.09%

Average Trading Volume: 5,000

Technical Sentiment Signal: Strong Buy

Current Market Cap: $256.4M

See more data about IMM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App